Clinical trials: Ticagrelor
Acute Coronary Syndrome, STEMI
Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg in Elderly Patients With ACS
Elderly individuals are increasingly represented among patients with acute coronary syndrome (ACS). Dual antiplatelet therapy (DAPT) with aspirin and an oral P2Y12 receptor inhibitor has an established role in the prevention of…
- Conditions
- Acute Coronary Syndrome, STEMI, NSTEMI, Coronary Artery Disease
- Trial name
- PlinytheElder (NCT04739384)
- Testing
- Ticagrelor 90mg, Ticagrelor 60 mg
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Federico II University
Ischemic Stroke
Ticagrelor Versus Cilostazol in Minor Ischemic Stroke or TIA
Along with the current clinical trial, the efficacy and safety of ticagrelor and aspirin administered within the first 24 hours of first-ever ischemic stroke compared to cilostazol and aspirin were assessed through NIHSS, mRS…
- Trial name
- NCT06196047
- Testing
- Ticagrelor 90 MG, Cilostazol 100 MG
- Where
- Egypt
- Volunteers
- 900 people
- Sponsor
- Kafrelsheikh University
Coronary Artery Disease (CAD)
GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation
After a stent procedure, it is common practice to prescribe anti-platelet medication to prevent the blood from clotting. The main objective of this study is to determine if there is a better medication strategy to prevent blood…
- Trial name
- NCT01813435
- Testing
- Ticagrelor, Acetylsalicylic Acid, Clopidogrel
- Where
- 130 sites in Australia, Austria and 16 more
- Volunteers
- 15,991 people
- Sponsor
- ECRI bv
Coronary Heart Disease
Study on the Registration of Coronary Heart Disease Patients Undergoing PCI
Study on the registration of coronary heart disease patients undergoing PCI in Chinese's population. Get the incidence of adverse events in these patients after PCI, a clear type of adverse reaction, forms, influencing factors…
- Trial name
- NCT02888652
- Testing
- antiplatelet agents(Clopidogrel or Ticagrelor)
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- The Third Xiangya Hospital of Central South University
Ischemic Stroke
Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke
Along with the current clinical trial, the efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever large-vessel ischemic stroke compared to 200 mg cilostazol were assessed through…
- Trial name
- NCT06202755
- Testing
- Ticagrelor 90 MG, Cilostazol 100 MG
- Where
- Egypt
- Volunteers
- 580 people
- Sponsor
- Kafrelsheikh University
Ischemic Stroke, Patent Foramen Ovale
Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study
A registry of patients from the Asia-Pacific region with PFO and ischemic stroke, designed to study the characteristics, investigations, treatment and outcomes using real-world data.
- Trial name
- PACIFIC-PFO (NCT06983795)
- Testing
- PFO closure using approved PFO closure devices, Surgical PFO closure, Medical management
- Where
- Singapore
- Volunteers
- 1,000 people
- Sponsor
- National University Hospital, Singapore
Acute Coronary Syndrome
Timing of Coronary Artery Bypass Surgery Among Patients With Acute Coronary Syndromes Initially on Ticagrelor
Ticagrelor, a more potent P2Y12 inhibitor, has been shown to reduce major adverse cardiac events (MACE) in acute coronary syndromes (ACS). It is increasingly used as a first line therapy in ACS.
- Trial name
- RAPID CABG (NCT02668562)
- Testing
- Early CABG (Day 2-3 after ticagrelor discontinuation), Delayed CABG (Day 5-7 after ticagrelor discontinuation)
- Where
- 2 sites in Canada
- Volunteers
- 143 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Cardiovascular Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects
Part A of this study is a Phase 1, First-in-human (FiH), randomized, single-blind, placebo controlled study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD3366 following single…
- Trial name
- NCT04588727
- Testing
- AZD3366, Ticagrelor, acetylsalicylic acid (ASA)
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hibernation, Myocardial, Complete Occlusion of Coronary Artery
The Success of Opening Single CTO Lesions to Improve Myocardial Viability Study (SOS-comedy)
The purpose of this study is to investigate the effect of percutaneous coronary intervention (PCI) on myocardial viability in coronary artery disease patients with single coronary total occlusion (CTO) lesions.
- Trial name
- NCT02767401
- Testing
- stenting or balloon expansion, aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
Myocardial Infarction, STEMI
Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment (POPular Genetics)
Rationale: the use of antiplatelet drugs (i.e. clopidogrel, ticagrelor or prasugrel) is crucial in the treatment of patients undergoing percutaneous coronary intervention (PCI) with stent implantation to prevent atherothrombotic…
- Trial name
- NCT01761786
- Testing
- CYP2C19 genotyping
- Where
- 10 sites in Belgium, Italy and 1 more
- Volunteers
- 2,700 people
- Sponsor
- Vera HM Deneer
Bleeding Complications
Clopidogrel Monotherapy in Patients With High Bleeding Risk
The goal of this research is to show that a shorter duration of two antiplatelet medications (compared to the standard of care) is safe and effective while reducing the risk of bleeding complications.
- Trial name
- NCT05223335
- Testing
- Clopidogrel, Prasugrel, Tricagrelor
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Mayo Clinic
Cardiovascular Disease, Stable Angina
Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI
Ticagrelor therapy has been shown to reduce the rates of cardiovascular events and all-cause mortality compared to clopidogrel therapy in patients with acute coronary syndromes (ACS).
- Conditions
- Cardiovascular Disease, Stable Angina, Myocardial Infarction, Coronary Artery Disease
- Trial name
- NCT02012140
- Testing
- ticagrelor
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- LifeBridge Health
Diabetes Mellitus, Type 2
PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor
The purpose of this study is to determine whether Ticagrelor has a protective effect on microcirculation during percutaneous coronary interventions in patients with Diabetes mellitus type II or in a pre-diabetic status.
- Trial name
- PREDICT (NCT02698618)
- Testing
- Diagnostic, Randomization, PCI
- Where
- 3 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Fundacion Investigacion Interhospitalaria Cardiovascular
Ischemic Stroke
Ticagrelor Versus Clopidogrel in Ischemic Stroke
Along with the current clinical trial, the efficacy and safety of 180 mg loading dose of ticagrelor administered within the first 24 hours of first-ever ischemic stroke compared to 300 mg clopidogrel were assessed through NIHSS…
- Trial name
- NCT05553613
- Testing
- Ticagrelor 90 MG Oral Tablet, Clopidogrel tablet
- Where
- Egypt
- Volunteers
- 900 people
- Sponsor
- Kafrelsheikh University
Cardiac Dysfunction
Population Pharmacokinetics of Teicoplanin, Levofloxacin, Piperacillin/Tazobactam, Meropenem, Vancomycin, Remifentanil, Cefepime, Cefpirome, Sufentanil, Midazolam, Clopidogrel, Ticagrelor, Prasugrel During Veno-arterial Extracorporeal Membrane Oxygenation (VA ECMO)
Extracorporeal membrane oxygenation (ECMO) is the device which increases the supply of oxygen to the body tissues in vitro and to assist in heart and lung function.
- Trial name
- NCT02581280
- Testing
- Residual blood
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- Yonsei University
Coronary Artery Disease
STEEL Percutaneous Coronary Intervention
The principal hypothesis of this study is that two different maintenance regimens of ticagrelor are safe, tolerable and associated with significant inhibition of erythrocyte adenosine reuptake compared to clopidogrel in patients…
- Trial name
- STEEL-PCI (NCT02327624)
- Testing
- Clopidogrel, Ticagrelor 60, Ticagrelor 90
- Where
- United Kingdom
- Volunteers
- 180 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Myocardial Infarction
Effect of Diabetes and Hepatic Enzymes Mutation on Clopidogrel VS Ticagrelor Activity in Myocardial Infarction (MI) Patients Undergoing Primary Percutaneous Coronary Intervention (PCI)
In this study the combined effect of diabetes mellitus and cyp2c19 polymorphism on platelet aggregation inhibitory activity of the highest traditionally used loading dose 600 mg clopidogrel and ticagrelor 180 mg loading dose will…
- Trial name
- NCT03613857
- Testing
- Clopidogrel, Ticagrelor 90mg
- Where
- Egypt
- Volunteers
- 1,022 people
- Sponsor
- Cairo University
Non ST Segment Elevation Acute Coronary Syndrome
Safety and Efficacy of Low-Dose Ticagrelor in Chinese Patients With NSTE-ACS
Ticagrelor is an oral, reversibly-binding, direct-acting P2Y12 receptor antagonist used clinically for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS).
- Trial name
- NCT02415803
- Testing
- low-dose ticagrelor, conventional-dose ticagrelor, Clopidogrel
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Coronary Stenoses
TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI
This study evaluates the efficacy and safety of tailored antithrombotic therapy with early (<6-month post-PCI) intensified (low-dose ticagrelor [120 mg loading, then 60 mg bid maintenance] and aspirin) and late (>6-month…
- Trial name
- TAILORED-CHIP (NCT03465644)
- Testing
- Tailored antithrombotic strategy, Conventional antithrombotic strategy
- Where
- 22 sites in South Korea
- Volunteers
- 2,018 people
- Sponsor
- Duk-Woo Park, MD
Coronary Artery Disease, Ischemic Heart Disease
Comparing T-stenting And Minimal Protrusion With External Minicrush for Treatment of Complex Coronary Bifurcation
Nowadays, no studies compare the T-stenting And Minimal Protrusion (TAP) and External Minicrush techniques in treating complex coronary bifurcation, so eventually, procedural, clinical and safety differences remain unknown.
- Conditions
- Coronary Artery Disease, Ischemic Heart Disease, Chronic Coronary Syndrome, Acute Coronary Syndrome
- Trial name
- NCT06484647
- Testing
- Percutaneous Coronary Intervention
- Where
- Italy
- Volunteers
- 382 people
- Sponsor
- San Luigi Gonzaga Hospital